imu-201
Vaccineexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 31, 2020 (NCT04432207)
Timeline
Indications
Mechanism of action
- Programmed cell death protein 1Immunity, active
PDCD1 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06692959 | Phase 2 | Dec 1, 2024 | Australasian Gastro-Intestinal Trials Group, Moorgreen Hospital, Southampton |
| NCT04432207 | Phase 1 | Jul 31, 2020 | Imugene Limited |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Australasian Gastro-Intestinal Trials Group | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Imugene Limited | For profit | 1 | 1 | 1 | 2020 |
| Moorgreen Hospital, Southampton | Academic/Hospital | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1